Get the Stockscreener App
1.825
1.35%
-0.025
Acurx Pharmaceuticals Inc stock is traded at $1.825, with a volume of 12,334.
It is down -1.35% in the last 24 hours and down -15.12% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
See More
Previous Close:
$1.85
Open:
$1.82
24h Volume:
12,334
Relative Volume:
0.26
Market Cap:
$29.40M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-1.615
EPS:
-1.13
Net Cash Flow:
$-9.80M
1W Performance:
-5.92%
1M Performance:
-15.12%
6M Performance:
-15.90%
1Y Performance:
-44.36%
1-Day Range:
$1.80
$1.8294
1-Week Range:
$1.80
$1.95
52-Week Range:
$1.52
$5.28
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the... - Markets Insider
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - AccessWire
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH) - AccessWire
AccreditedEvents.com Unveils Premier Lineup for November and December Investor Events - Big News Network
Acurx reports positive Phase 2 results for CDI treatment ibezapolstat - Investing.com India
Acurx reports positive Phase 2 results for CDI treatment ibezapolstat By Investing.com - Investing.com South Africa
Acurx Ready To Expand Pipeline With Anthrax Treatment (NASDAQ:ACXP) - Seeking Alpha
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference - StockTitan
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement - StockTitan
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - StockTitan
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support - Bluefield Daily Telegraph
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST - AccessWire
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST - The Hastings Tribune
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Growth in Short Interest - Defense World
Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity - Investing.com
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues - StockTitan
Acurx Announces Anthrax Susceptibility to ACX-375 Analogues - Global Biodefense
Acurx readies ibezapolstat for Phase 3 CDI trials By Investing.com - Investing.com Australia
Acurx readies ibezapolstat for Phase 3 CDI trials - Investing.com
Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection - TipRanks
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium - StockTitan
Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Down 7% - Defense World
ACM Research, Inc. (ACMR) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
ACM Research Inc (ACMR) stock: A year of ups and downs - US Post News
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Carborundum Universal shares surge over 4% following acquisition and investment plans - Business Upturn
ACM Research Inc [ACMR] Insider Activity: An Update for Investors - Knox Daily
Ratios Uncovered: Breaking Down ACM Research Inc (ACMR)’s Trailing Twelve Months Metrics - The Dwinnex
Healthy Upside Potential: ACM Research Inc (ACMR) - SETE News
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET - StreetInsider.com
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 5.4% in August - Defense World
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, - Daily Guardian Canada
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT - GlobeNewswire
ACXPAcurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
We're A Little Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Rate - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
New to The Street Announces Episode 590, Five Corporate - GlobeNewswire
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update - Defense World
Zentalis Pharmaceuticals, Inc. Expected to Earn Q3 2024 Earnings of ($0.86) Per Share (NASDAQ:ZNTL) - Defense World
HC Wainwright Analysts Increase Earnings Estimates for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World
Q3 2024 Earnings Estimate for Akero Therapeutics, Inc. (NASDAQ:AKRO) Issued By HC Wainwright - Defense World
HC Wainwright Weighs in on Akebia Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:AKBA) - Defense World
Cymat Technologies (CVE:CYM) Trading 29.6% Higher - Defense World
Acurx Pharmaceuticals (NASDAQ:ACXP) Earns Buy Rating from HC Wainwright - Defense World
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DELUCCIA ROBERT J | Director |
Jan 03 '24 |
Option Exercise |
3.55 |
19,737 |
70,066 |
960,935 |
| LUCI DAVID P | President and CEO |
Jan 03 '24 |
Option Exercise |
3.55 |
19,737 |
70,066 |
1,048,197 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):